Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer

Clinical Trial ID NCT01510288

Rank	Title	Journal	Year	PubWeight™‹?›
1	Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.	Lancet Oncol	2012	3.10
2	Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances.	Ther Adv Vaccines	2014	0.86
3	Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab.	J Immunother Cancer	2014	0.86
4	Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival.	Int J Cancer	2014	0.80
5	Application of radiation technology in vaccines development.	Clin Exp Vaccine Res	2015	0.78
6	The Promise of Preventive Cancer Vaccines.	Vaccines (Basel)	2015	0.77
7	Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells.	Oncoimmunology	2015	0.75